All News
RheumNow Podcast – New World Order (3.27.20)
Dr. Jack Cush reviews the news and COVID developments from this past week.
Read Article
ACR Infusion Guidance During COVID-19 Crisis
The American College of Rheumatology (ACR) has published a guidance document on infusions and office based therapies.
Read Article
Dr. Artie Kavanaugh - Don't Stop!
Drs. Cush and Kavanaugh discuss the downside of stopping hydroxychloroquine, DMARDs and biologics in lupus, RA and pregnancy.
Read Article
Global Rheumatology Alliance Registry Will Study COVID-19
In the midst of a global pandemic of the 2019 Novel coronavirus acute respiratory disease (COVID-19), a small handful of Rheumatologists gathered on social media to collectively grapple with the impact of this virus on vulnerable populations with rheumatic disease.
Infusions in the Time of Coronavirus
As they say, necessity is the mother of invention. After years of bemoaning the challenges of telemedicine, our rheumatology clinic transition entirely to a remote clinic in the space of a week.
Read Article
COVID-19 Rheumatology News
With the COVID-19 pandemic dynamically changing, we have provided several news items germane to the Rheumatologist.
Read Article
The COVID-19 Global Rheumatology Registry
As the highly virulent SARS-CoV-2 spreads over the world, uncertainty and fear for our patients with rheumatic diseases mount.
Read Article
RheumNow Podcast- Corona Increases RA Risk (3.13.20)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
Switching Biologics in JIA
While there are numerous agents approved for use in juvenile idiopathic arthritis, little is know about actual use biological disease-modifying antirheumatic drug (DMARD) use or switching in the biologic era. A cohort comparison study has shown that after an unsuccessful trial of a first biologic, changing to a second TNFi is as effective as switching to a non-TNFi biologic.
Read Article
Malignancies with Giant Cell Arteritis
The Journal of Rheumatology reports the findings of a Swedish population-based cohort study of biopsy-proven giant cell arteritis (GCA) patients showing that the overall risk for cancer was not increased; yet there appears to be an increased risk for leukemia and a decreased risk for breast and u
Read Article
EMA Final Recommendations on VTE Risk with Tofacitinib
On 14 November 2019 the European Medicines Agency (EMA) concluded that Xeljanz (tofacitinib) could increase the risk of blood clots in the lungs and in deep veins in patients who are already at high risk. These recommendations have been formally published and are intended for EU nation
Read Article
Hospitalized GPA - Higher morbidity, Mortality and Cost
Rheumatology reports on a study of patients with granulomatosis with polyangiitis (GPA) showing worse outcomes and higher costs when hospitalized with GPA.
Read Article
Need for Disruptive Innovation in Rheumatology
A full-read, novel Viewpoint article published in the Annals of Rheumatic Disease (Huizinga TWJ, et al) spotlights a recent international meeting of big thinkers, scientific collaborators and industry dedicated to innovation in rheumatology.
Read Article
Venom Peptide-Steroid Conjugate Effective in Collagen Induced Arthritis
Science Translational Medicine features a report from the Fred Hutchinson Cancer Research Center showing that a scopion venom peptide, coupled to steroid, can significantly reduce joint inflammation in a rat model of rheumatoid arthritis (RA).
Read Article
Drug Interactions with Cannabinoids
Cannbinoids are widely available and used for a variety of indications, but little is known about their safety and their potential for drug interactions. The Canadian Medical Journal has published a review of drug interactions with cannabinoids, many of which are mediated by cytochrome-P450 metabolism.
Read Article
Folate Levels Protect from CV Mortality in RA
In a study of rheumatoid arthritis (RA) patients, JAMA reports that serum folate level of greater than 4.3 ng/mL was associated with lower CV mortality risk.
Read Article
Interleukin-37 Targeting in Gout
The Annals of Rheumatic Disease reports that interleukin- 27 (IL-37) may play an important role in the pathogenesis of gout, paving the way for future therapy with recombinant IL-37 in gouty arthritis.
Read Article
RheumNow Podcast- Methotrexate Mechanisms (2.28.20)
Dr Jack Cush Reviews the news and journal articles from the past week on RheumNow.com
Read Article
Fatigue Looms Large in Lupus
Fatigue is an important component of the disease experience in systemic lupus erythematosus (SLE), and can have a profound impact on patients' perception of well-being, Italian researchers reported.
Read Article
Why You Should Come to RheumNow Live March 13th
RheumNow Live kicks off its second annual meeting - a little, big meeting in Fort Worth - in just 2 weeks and I think you should be there.
Read Article